TetraLogic Announces Termination of Public Offering
06. Mai 2015 12:52 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial
06. Mai 2015 10:14 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Pricing of $25 Million Public Offering
01. Mai 2015 08:56 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 1, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Public Offering of Common Stock
30. April 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
21. April 2015 08:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
20. April 2015 08:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa. and KENILWORTH, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and...
TetraLogic to Present at the 14th Annual Needham Healthcare Conference
09. April 2015 10:11 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...
TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update
26. Februar 2015 16:10 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Feb. 26, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
18. Dezember 2014 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Dec. 18, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with...
TetraLogic Provides Update on Ovarian Cancer Study
16. Dezember 2014 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Dec. 16, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with...